The global nanomedicine market reached $63.8 billion in 2010 and $72.8
billion in 2011. The market is expected to grow to $130.9 billion by 2016 at a
compound annual growth rate (CAGR) of 12.5% between years 2011 and 2016.
The central nervous system (CNS) products market reached $11.7 billion in
2010 and $14.0 billion in 2011. It is expected to grow to $29.5 billion by
2016, a CAGR of 16.1% between years 2011 and 2016.
The anticancer products market reached $25.2 billion in 2010 and $28.0
billion in 2011. It is expected to reach $46.7 billion by 2016, a CAGR of
10.8% between years 2011 and 2016.
SUMMARY FIGURE
NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, 2009-2016
($ BILLIONS)
Source: BCC Research
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry
analyses to help readers quantify and qualify the market for prescription drug
products incorporating nanotechnology features. Important trends are
identified and sales forecasts by product categories and major country markets
are provided through 2016; these are based on industry sources and considered
assessment of the regulatory environment, healthcare policies, demographics,
and other factors that directly affect the nanomedicine-related drug market.
The wider economic environment is also taken into account.
The report examines strategies employed by companies specializing in
nanomedicine to meet the challenges of this highly competitive market.
REASONS FOR DOING THE STUDY
Nanomedicine is already an established market. Unlike some other potential
applications of nanotechnology, which are still largely experimental,
nanomedicine has already produced a number of significant products in which
the nano dimension has made a significant contribution to product
effectiveness. Now that aspects of the nanomedicine market are established, it
is appropriate to review the technology, see its practical applications so
far, evaluate the participating companies and look to its future.
SCOPE OF REPORT
This report discusses the implications of technology and commercial trends in
the context of the current size and growth of the pharmaceutical market, both
in global terms and analyzed by the most important national markets. The
important technologies supporting nanomedicine are reviewed, and the nature
and structure of the nanomedicine industry is discussed with profiles of the
leading 60+ companies, including recent M&A activity. Five-year sales
forecasts are provided for the national markets and the major therapeutic
categories of products involved.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are
projected at 2011-dollar value without attempting to predict the effect of
inflation/deflation.
Therapeutic categories quantified and forecast include cancer, CNS diseases,
infections and cardiovascular. Country markets analyzed are the U.S., Japan,
Germany, France, UK, Italy, and Spain.
METHODOLOGY
Primary research includes interviews with leading individuals in nanomedicine
companies and industry associations. Primary sources of published data include
company annual reports, SEC filings, and government and industry publications.
Secondary sources consist of literature searches, industry journals and other
commercial publications. Data for market estimates and forecasts are pooled
from a range of sources, critically assessed by BCC.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives,
government agencies and regulatory bodies, and surveys of physicians and
pharmacists. Company annual reports and SEC filings, journal articles, and
data from healthcare institutions were also mined, as well as publications of
relevant trade associations.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical
markets for 20 years. He is the author of previous reports on the nanomedicine
marketplace as well as analyses of major therapeutic categories and the
pharmaceutical regulatory environment.
Table of Contents
Nanotechnology in Medical Applications: The Global Market
Chapter - 1: INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
MARKET ANALYSES AND FORECASTS
METHODOLOGY
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ON-LINE SERVICES
DISCLAIMER
Chapter - 2: SUMMARY
DEFINITION
RESEARCH AND COMMERCIALIZATION
APPLICATIONS
MARKET
Chapter - 3: OVERVIEW
MEDICAL NANOTECHNOLOGY: NANOMEDICINE
FUTURE POSSIBILITIES
MARKET POTENTIAL
ABOUT NANOTECHNOLOGY
THE MANY USES OF NANOTECHNOLOGY
THE TOOLS OF NANOTECHNOLOGY
RISKS OF NANOTECHNOLOGY
NANOTECHNOLOGY IN THE MARKETPLACE
Chapter - 4: NANOMEDICINE
DEVELOPMENT OF NANOMEDICAL TECHNOLOGIES
THERAPEUTIC USES OF NANOMEDICINE
THE RISK FACTOR
Table 1: NANOMEDICINE TIMESCALE
Table 2: MAIN NANOTECHNOLOGIES USED IN MEDICINE, WITH APPLICATIONS
Chapter - 5: MARKETS FOR NANOMEDICINE
MARKET DRIVERS
MARKET ESTIMATES AND FORECASTS
GLOBAL NANOMEDICINE MARKET
MAIN PRODUCT CATEGORIES
Chapter - 6: THE NANOMEDICINE INDUSTRY
ABLYNX
ABRAXIS BIOSCIENCE
ACCESS
ACRYMED INC.
ACUSPHERE
ADVANCED MAGNETICS
ALLTRACELL
ALPHARX INC.
ANSON NANO-BIOTECHNOLOGY (ZHUHAI) CO. LTD
APHIOS CORP.
BIOCRYSTAL LTD
BIOFORCE NANOSCIENCES
BIO-GATE
BIOPHAGE PHARMA
BIOPHAN TECHNOLOGIES
BIOSANTE PHARMACEUTICALS INC.
CALANDO PHARMACEUTICALS
CAMURUS AB
CAPSULUTION PHARMA AG
COMBIMATRIX CORPORATION
DAMAGE PREVENTION CONCEPT
ELAN DRUG TECHNOLOGIES
ENZON PHARMACEUTICALS, INC.
FARFIELD SCIENTIFIC
GE HEALTHCARE LIFE SCIENCES
GILEAD
HEALTHPLUS INTERNATIONAL INC.
IGI INC.
JR NANOTECH, PLC
KEREOS, INC.
KEYSTONE NANO, INC.
KLEINDIEK NANOTECHNIK GMBH
LABOPHARM INC.
LIPLASOME PHARMA A/S
LUMERA CORPORATION
MAGFORCE NANOTECHNOLOGIES AG
MAGNAMEDICS GMBH
MICROFLUIDICS INTERNATIONAL CORPORATION
MIV THERAPEUTICS INC.
MOLECULAR PROFILES
NANOBIO CORPORATION
NANOBIOTIX
NANOCARRIER CO LTD
NANOCYTE INC
NANOGEN INC
NANOINK, INC.
NANOLOGIX, INC.
NANOMED PHARMACEUTICALS, INC.
NANOMIX INC
NANOPHARM AG
NANOSPECTRA BIOSCIENCES, INC.
NANOSPHERE, INC.
NANOSTRUCTURES, INC.
NANOSYN INC
NANOTHERAPEUTICS, INC.
NANOTROPE INC.
NANOVIRICIDES INC
NUCRYST PHARMACEUTICALS
NUTRALEASE
ORTHOVITA INC.
PIONEER SURGICAL TECHNOLOGY
PSIVIDA LTD
QIAGEN N.V.
SKYEPHARMA PLC
SOLUBEST
STARPHARMA HOLDINGS LTD
TECAN GROUP LTD.
TELOMOLECULAR CORPORATION
Chapter - 7: APPENDIX
Table 27: GLOSSARY
List of Tables
Summary Table: NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, THROUGH 2016
Table 1: NANOMEDICINE TIMESCALE
Table 2: MAIN NANOTECHNOLOGIES USED IN MEDICINE, WITH APPLICATIONS
Table 3: MARKETED LIPOSOME NANOPHARMACEUTICALS
Table 4: NANOCRYSTAL PHARMACEUTICALS
Table 5: MARKETED AND DEVELOPMENTAL PRODUCTS IN MICELLE FORM
Table 6: MARKETED PRODUCTS WITH NANO-ENHANCED DELIVERY
